<SEC-DOCUMENT>0001213900-20-025507-index.html : 20200908
<SEC-HEADER>0001213900-20-025507.hdr.sgml : 20200908
<ACCEPTANCE-DATETIME>20200908070158
ACCESSION NUMBER:		0001213900-20-025507
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20200908
FILED AS OF DATE:		20200908
DATE AS OF CHANGE:		20200908

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAMADA LTD
		CENTRAL INDEX KEY:			0001567529
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35948
		FILM NUMBER:		201162931

	BUSINESS ADDRESS:	
		STREET 1:		2 HOLTZMAN ST., SCIENCE PARK
		CITY:			REHOVOT
		STATE:			L3
		ZIP:			7670402
		BUSINESS PHONE:		97289406472

	MAIL ADDRESS:	
		STREET 1:		2 HOLTZMAN ST., SCIENCE PARK
		CITY:			REHOVOT
		STATE:			L3
		ZIP:			7670402
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea126541-6k_kamadaltd.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
Document 1 - file: ea126541-6k_kamadaltd.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea126541ex99-1_kamada.htm
<DESCRIPTION>KAMADA ANNOUNCES COMPLETION OF ENROLLMENT AND INITIAL INTERIM RESULTS FROM ITS PHASE 1/2 CLINICAL TRIAL IN ISRAEL OF ITS PLASMA-DERIVED HYPERIMMUNE IMMUNOGLOBULIN (IGG) PRODUCT AS A POTENTIAL TREATMENT FOR CORONAVIRUS DISEASE (COVID-19)
<TEXT>
Document 2 - file: ea126541ex99-1_kamada.htm

</DOCUMENT>
</SEC-DOCUMENT>